Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

China Announces Blacklist for Medical Bribery and Substandard Products

publication date: Jan 6, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China will institute an official blacklisting system of drugmakers and medical device manufacturers to punish them for bribing officials or providing substandard products.  The system was announced by the National Health and Family Planning Commission recently. It will prevent a company from selling products in any province for two years where it has been found guilty of an infraction. If the company commits two infractions in a five-year period, it will be banned from selling its products anywhere in China, also for two years. The blacklist will officially begin operations on March 1. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors